Overview

A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

Status:
Completed

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

This study assessed the comparability of the pharmacokinetics (PK) of epoetin following intravenous administration of Hospira Epoetin and Epogen/Epoetin Alfa (Amgen) in patients with chronic renal failure receiving hemodialysis treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer

Treatments:

Epoetin Alfa